Molecular Cancer Therapeutics publishes translational research studies focused on the discovery and preclinical development of therapeutic agents for oncology. To reflect the evolving field of therapeutics, the journal’s interest extends to all selective drugs including small molecule inhibitors, antibody-drug conjugates, antibody cytokine fusions, bispecific antibodies, cell therapies, gene therapies, radio-immunotherapeutics, vaccines, viral therapies, and other experimental approaches in oncology.

Specific areas of interest are the disclosure of translational investigations of novel drug therapies, preclinical studies of approved therapeutics (including their combination with radiation therapy), mechanisms of action, mitigation of resistance, biomarkers of response, novel models and technology, and applications of big data in drug discovery.